Specializes in Peptides

Two Decades of Dedication:

From our humble strides, unfolds the grandest journeys.

010203

Product Categories

Main Product

01020304

About

Hybio Pharmaceutical Co., Ltd.

Founded in 1998, Hybio is a leading peptides company in China specializing in the development, manufacture and commercialization of therapeutic peptides API and peptide-based drugs, listed in market with stock code 300199.

With more than 20 years’ experience, Hybio offers a full range of synthetic peptide products and services, as well as CRO and CDMO for research, clinical development and commercial application for pharmaceutical companies worldwide. The main products have been applied to treat the digestive diseases, cardio-cerebro-vascular diseases, diabetes, infectious disease, cancer, and senile diseases, etc

our solution

We provide you with

Customized Peptide

Drawing on our expertise in peptides, along with our robust R&D platform, we at Hybio offer customized peptides of varying complexity. These are synthesized using both solid-phase and liquid-phase processes to cater to the diverse needs of our global customers.

CRO&CDMO

We offer a full range of peptides globally, such as Liraglutide, Semaglutide and Exenatide for diabetes; Terlipressin, Desmopressin and Linaclotide for digestive tract and metabolic system; Ganirelix, Cetrorelix and Atosiban for obstetrics and gynecology, etc.

OUR ADVANTAGE

Our core competitiveness

in 2011, Hybio was listed on Shenzhen Stock Exchange Market (stock code 300199), and became the first listed enterprise of manufacturing peptide drugs in China.